Axelyf, Inc.


Axelyf is an R&D-focused biotechnology company founded in Iceland (with a U.S. parent corporation) that develops lipid nanoparticle (LNP) delivery technologies and complementary chemistries to enable safer, more potent RNA medicines. The team combines nanotechnology formulation experience, a proprietary molecular lipid library, AI-driven modeling for LNP performance, and prodrug research to advance preclinical mRNA and gene-editing delivery programs and partner with external developers.

Industries

N/A


Products

Proprietary lipid library for LNP formulation

An integrated molecular library of novel lipids and formulation variants developed to identify potent delivery compounds for mRNA and other biomolecular cargos.

AI model for nanoparticle performance prediction

A machine-learning model that predicts LNP potency and compares candidates on a common scale across heterogeneous datasets to guide virtual screening and candidate selection.

Prodrug candidate for inflammatory disease (preclinical)

A proprietary prodrug candidate developed from a natural-product scaffold with demonstrated efficacy in a preclinical arthritis model.


Services

Partnerships and collaborative development

Collaborative discovery and development agreements to apply lipid library and formulation expertise to partner programs; multi-year collaborations for chemistry and bio-analytical support.

Expertise Areas

  • Lipid nanoparticle formulation and optimization
  • AI-driven modeling for nanoparticle design
  • mRNA delivery and gene-editing delivery strategies
  • Nanotechnology formulation and LNP characterization
  • Show More (5)

Key Technologies

  • Lipid nanoparticles (LNPs)
  • AI / machine learning for nanoparticle modeling
  • Digital molecular libraries
  • Prodrug chemistry
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.